Derangements of amino acids in cachectic skeletal muscle are caused by mitochondrial dysfunction.


Journal

Journal of cachexia, sarcopenia and muscle
ISSN: 2190-6009
Titre abrégé: J Cachexia Sarcopenia Muscle
Pays: Germany
ID NLM: 101552883

Informations de publication

Date de publication:
02 2020
Historique:
received: 13 02 2019
revised: 12 07 2019
accepted: 25 08 2019
pubmed: 23 1 2020
medline: 29 5 2021
entrez: 23 1 2020
Statut: ppublish

Résumé

Cachexia is the direct cause of at least 20% of cancer-associated deaths. Muscle wasting in skeletal muscle results in weakness, immobility, and death secondary to impaired respiratory muscle function. Muscle proteins are massively degraded in cachexia; nevertheless, the molecular mechanisms related to this process are poorly understood. Previous studies have reported conflicting results regarding the amino acid abundances in cachectic skeletal muscle tissues. There is a clear need to identify the molecular processes of muscle metabolism in the context of cachexia, especially how different types of molecules are involved in the muscle wasting process. New in situ -omics techniques were used to produce a more comprehensive picture of amino acid metabolism in cachectic muscles by determining the quantities of amino acids, proteins, and cellular metabolites. Using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging, we determined the in situ concentrations of amino acids and proteins, as well as energy and other cellular metabolites, in skeletal muscle tissues from genetic mouse cancer models (n = 21) and from patients with cancer (n = 6). Combined results from three individual MALDI mass spectrometry imaging methods were obtained and interpreted. Immunohistochemistry staining for mitochondrial proteins and myosin heavy chain expression, digital image analysis, and transmission electron microscopy complemented the MALDI mass spectrometry imaging results. Metabolic derangements in cachectic mouse muscle tissues were detected, with significantly increased quantities of lysine, arginine, proline, and tyrosine (P = 0.0037, P = 0.0048, P = 0.0430, and P = 0.0357, respectively) and significantly reduced quantities of glutamate and aspartate (P = 0.0008 and P = 0.0124). Human skeletal muscle tissues revealed similar tendencies. A majority of altered amino acids were released by the breakdown of proteins involved in oxidative phosphorylation. Decreased energy charge was observed in cachectic muscle tissues (P = 0.0101), which was related to the breakdown of specific proteins. Additionally, expression of the cationic amino acid transporter CAT1 was significantly decreased in the mitochondria of cachectic mouse muscles (P = 0.0133); this decrease may play an important role in the alterations of cationic amino acid metabolism and decreased quantity of glutamate observed in cachexia. Our results suggest that mitochondrial dysfunction has a substantial influence on amino acid metabolism in cachectic skeletal muscles, which appears to be triggered by diminished CAT1 expression, as well as the degradation of mitochondrial proteins. These findings provide new insights into the pathobiochemistry of muscle wasting.

Sections du résumé

BACKGROUND
Cachexia is the direct cause of at least 20% of cancer-associated deaths. Muscle wasting in skeletal muscle results in weakness, immobility, and death secondary to impaired respiratory muscle function. Muscle proteins are massively degraded in cachexia; nevertheless, the molecular mechanisms related to this process are poorly understood. Previous studies have reported conflicting results regarding the amino acid abundances in cachectic skeletal muscle tissues. There is a clear need to identify the molecular processes of muscle metabolism in the context of cachexia, especially how different types of molecules are involved in the muscle wasting process.
METHODS
New in situ -omics techniques were used to produce a more comprehensive picture of amino acid metabolism in cachectic muscles by determining the quantities of amino acids, proteins, and cellular metabolites. Using matrix-assisted laser desorption/ionization (MALDI) mass spectrometry imaging, we determined the in situ concentrations of amino acids and proteins, as well as energy and other cellular metabolites, in skeletal muscle tissues from genetic mouse cancer models (n = 21) and from patients with cancer (n = 6). Combined results from three individual MALDI mass spectrometry imaging methods were obtained and interpreted. Immunohistochemistry staining for mitochondrial proteins and myosin heavy chain expression, digital image analysis, and transmission electron microscopy complemented the MALDI mass spectrometry imaging results.
RESULTS
Metabolic derangements in cachectic mouse muscle tissues were detected, with significantly increased quantities of lysine, arginine, proline, and tyrosine (P = 0.0037, P = 0.0048, P = 0.0430, and P = 0.0357, respectively) and significantly reduced quantities of glutamate and aspartate (P = 0.0008 and P = 0.0124). Human skeletal muscle tissues revealed similar tendencies. A majority of altered amino acids were released by the breakdown of proteins involved in oxidative phosphorylation. Decreased energy charge was observed in cachectic muscle tissues (P = 0.0101), which was related to the breakdown of specific proteins. Additionally, expression of the cationic amino acid transporter CAT1 was significantly decreased in the mitochondria of cachectic mouse muscles (P = 0.0133); this decrease may play an important role in the alterations of cationic amino acid metabolism and decreased quantity of glutamate observed in cachexia.
CONCLUSIONS
Our results suggest that mitochondrial dysfunction has a substantial influence on amino acid metabolism in cachectic skeletal muscles, which appears to be triggered by diminished CAT1 expression, as well as the degradation of mitochondrial proteins. These findings provide new insights into the pathobiochemistry of muscle wasting.

Identifiants

pubmed: 31965747
doi: 10.1002/jcsm.12498
pmc: PMC7015243
doi:

Substances chimiques

Amino Acids 0
Mitochondrial Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-240

Informations de copyright

© 2019 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.

Références

Anal Chem. 2018 Mar 6;90(5):3156-3164
pubmed: 29381867
Lancet Oncol. 2011 May;12(5):489-95
pubmed: 21296615
Annu Rev Nutr. 2004;24:377-99
pubmed: 15459982
Crit Rev Clin Lab Sci. 1993;30(3):223-72
pubmed: 8260072
J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):140-154
pubmed: 30680954
Nucleic Acids Res. 2007 Jan;35(Database issue):D521-6
pubmed: 17202168
Oncotarget. 2018 Apr 24;9(31):22001-22022
pubmed: 29774118
Nat Protoc. 2016 Aug;11(8):1428-43
pubmed: 27414759
Gastroenterology. 2006 Oct;131(4):1096-109
pubmed: 17030180
J Physiol. 2012 Jul 15;590(14):3349-60
pubmed: 22586215
PLoS One. 2014 Aug 11;9(8):e104643
pubmed: 25111602
Eur J Biochem. 1972 Feb 15;25(2):372-8
pubmed: 5039842
Aging (Albany NY). 2012 Feb;4(2):133-43
pubmed: 22361433
Br J Cancer. 2005 Oct 3;93(7):774-80
pubmed: 16160695
Int J Biochem Cell Biol. 2013 Jul;45(7):1399-409
pubmed: 23608519
Biochemistry. 1968 Nov;7(11):4030-4
pubmed: 4972613
J Cachexia Sarcopenia Muscle. 2017 Dec;8(6):1081-1083
pubmed: 29098794
FEBS Lett. 2001 Jan 12;488(1-2):34-8
pubmed: 11163791
Physiol Rev. 2009 Apr;89(2):381-410
pubmed: 19342610
PLoS One. 2011;6(9):e24650
pubmed: 21949739
Nat Med. 2000 May;6(5):513-9
pubmed: 10802706
BMC Bioinformatics. 2007 Mar 26;8:101
pubmed: 17386085
J Am Soc Nephrol. 2006 Jul;17(7):1807-19
pubmed: 16738015
Nat Rev Cancer. 2014 Nov;14(11):754-62
pubmed: 25291291
Mol Cell Proteomics. 2013 Oct;12(10):2901-10
pubmed: 23782541
J Vis Exp. 2017 Mar 28;(121):
pubmed: 28448058
Int J Mol Med. 2011 Jan;27(1):15-24
pubmed: 21069263
Bioinformatics. 2016 Dec 15;32(24):3852-3854
pubmed: 27542771
J Cachexia Sarcopenia Muscle. 2015 Mar;6(1):84-94
pubmed: 26136415
Biol Reprod. 2009 Feb;80(2):295-301
pubmed: 18971426
Semin Cell Dev Biol. 2016 Jun;54:11-9
pubmed: 26564688
J Natl Cancer Inst. 2015 Oct 12;107(12):djv274
pubmed: 26464423
Biochim Biophys Acta. 2008 Jul-Aug;1777(7-8):965-72
pubmed: 18486589
Physiol Rev. 2011 Oct;91(4):1447-531
pubmed: 22013216
J Cachexia Sarcopenia Muscle. 2013 Jun;4(2):145-55
pubmed: 23344889
Curr Opin Clin Nutr Metab Care. 2013 Nov;16(6):638-44
pubmed: 24100668
Exp Gerontol. 2006 Jul;41(7):653-7
pubmed: 16677792
PLoS One. 2014 Jan 29;9(1):e87776
pubmed: 24489962
J Cachexia Sarcopenia Muscle. 2020 Feb;11(1):226-240
pubmed: 31965747
Nat Rev Cancer. 2002 Nov;2(11):862-71
pubmed: 12415256
Curr Opin Clin Nutr Metab Care. 2005 Jan;8(1):41-51
pubmed: 15585999
Trends Pharmacol Sci. 1996 Jun;17(6):223-6
pubmed: 8763200
Annu Rev Nutr. 2002;22:87-105
pubmed: 12055339
Int J Mol Sci. 2018 Jul 30;19(8):
pubmed: 30061533

Auteurs

Thomas Kunzke (T)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Achim Buck (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Verena M Prade (VM)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Annette Feuchtinger (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Olga Prokopchuk (O)

Department of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.

Marc E Martignoni (ME)

Department of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.

Simone Heisz (S)

Else Kroener-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, TUM, Munich, Germany.
ZIEL-Institute for Food and Health, Nutritional Medicine Unit, TUM, Freising, Germany.

Hans Hauner (H)

Else Kroener-Fresenius-Center for Nutritional Medicine, Klinikum rechts der Isar, TUM, Munich, Germany.
ZIEL-Institute for Food and Health, Nutritional Medicine Unit, TUM, Freising, Germany.

Klaus-Peter Janssen (KP)

Department of Surgery, Klinikum rechts der Isar, TUM, Munich, Germany.

Axel Walch (A)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Michaela Aichler (M)

Research Unit Analytical Pathology, Helmholtz Zentrum München, Oberschleißheim, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH